CW July 2005
Volume 14Issue Number 7 July 2005 ISSN 10593802 Multi-targeted Therapy Slows Disease Progression in Metastatic Renal Cell CancerA novel targeted therapy can slow disease progression in advanced kidney cancer that no longer responds to standard therapies. The experimental drug AG-013736 led to substantial tumor shrinkage in metastatic renal cell carcinoma (RCC) unresponsive to cytokine therapy.
Go to Previous Page Go to Next Page Source & Additional Reading B. Rini, 41st Annual Meeting of the American Society of Clinical Oncology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
